락토바실루스 람노서스 GG 관련 과민성 대장 증후군(IBS)
B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.여러 RCT에서 IBS 증상, 특히 팽만감과 복통의 개선을 보였습니다. IBS-D 아형에서 효과가 가장 강하며 모든 IBS 아형에서 결과가 균일하지는 않습니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
여러 RCT에서 IBS 증상, 특히 팽만감과 복통의 개선을 보였습니다. IBS-D 아형에서 효과가 가장 강하며 모든 IBS 아형에서 결과가 균일하지는 않습니다.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
효과: None
None
대상 집단: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Randomized Controlled Trial
3 weeks
Double-blind
Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review …
Dose: None
vs: Placebo
Outcome: Pain outcomes
효과: None
None
대상 집단: IBS patients
Systematic Review
n=3
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic …
Dose: None
vs: None
Outcome: Abdominal pain frequency/intensity, constipation
효과: None
None
대상 집단: Children with FAPD or functional constipation
Systematic Review
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Dose: various probiotic strains
vs: placebo
Outcome: IBS symptom improvement in children
효과: LGG showed benefit in some studies
None
대상 집단: Children with IBS
Review
Probiotic Bacterial and Fungal Strains: Claims with Evidence.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: Various populations (probiotic claims review)
Review
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: IBD patients
Key Statistics
8
연구
1200
참여자
↑
Positive
B
등급
Referenced Papers
Journal of clinical …
2026
Nutrients
2024
5 인용
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 인용
Digestive diseases (Basel, …
2016
37 인용
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Systematic Review
Journal of pediatric …
2016
19 인용
The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts.
Systematic Review
Paediatric drugs
2015
122 인용
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 인용
BMC gastroenterology
2010
91 인용
Alimentary pharmacology & …
2007
102 인용
Asia Pacific journal …
2006
45 인용
Asia Pacific journal …
2006
Alimentary pharmacology & …
2005
398 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- aadprevention:
- 10-20 billion CFU/day (start with antibiotic, continue 7 days after)
상한량: Generally well-tolerated up to 40 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 3 weeks | Positive | -- |
| None | -- | Mixed | 3 |
| various probiotic strains | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | 26.0 weeks | Mixed | -- |
권장 복용 시간: On an empty stomach or 30 minutes before meals for optimal survival
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
- ⚠ Rare reports of bacteremia in severely immunocompromised individuals
- ⚠ Occasional loose stools during adjustment period
- ⚠ Very rare: systemic infection in critically ill patients with central venous catheters
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
- ● Antifungals (no known interaction but may affect gut flora balance)
일일 최대 섭취 허용량: Generally well-tolerated up to 40 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 락토바실루스 람노서스 GG help with 과민성 대장 증후군(IBS)?
Based on 8 studies with 1,200 participants, there is moderate evidence from clinical studies that 락토바실루스 람노서스 GG may support 과민성 대장 증후군(IBS) management. Our evidence grade is B (Good Evidence).
How much 락토바실루스 람노서스 GG should I take for 과민성 대장 증후군(IBS)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 락토바실루스 람노서스 GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 락토바실루스 람노서스 GG and 과민성 대장 증후군(IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 8 peer-reviewed studies with 1,200 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 과민성 대장 증후군(IBS)
락토바실루스 람노서스 GG 다른 건강 상태에 대한 근거
References
- [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
- [2] Silvia Salvatore et al.. Nutrients. 2024. Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review and Practical Insights. doi:10.3390/nu16030349 PubMed
- [3] Carrie A M Wegh et al.. J Clin Gastroenterol. 2018. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. doi:10.1097/MCG.0000000000001054 PubMed
- [4] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
- [5] Eleonora Giannetti et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. doi:10.1097/MPG.0000000000001220 PubMed
- [6] Sylvia Cruchet et al.. Paediatr Drugs. 2015. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. doi:10.1007/s40272-015-0124-6 PubMed
- [7] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
- [8] Anna Lyra et al.. BMC Gastroenterol. 2010. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. doi:10.1186/1471-230X-10-110 PubMed
- [9] K Kajander et al.. Aliment Pharmacol Ther. 2007. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. doi:10.1111/j.1365-2036.2007.03391.x PubMed
- [10] Seppo Salminen et al.. Asia Pac J Clin Nutr. 2006. Intestinal colonisation, microbiota and future probiotics? PubMed
- [11] Kajsa Kajander et al.. Asia Pac J Clin Nutr. 2006. Clinical studies on alleviating the symptoms of irritable bowel syndrome. PubMed
- [12] K Kajander et al.. Aliment Pharmacol Ther. 2005. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. doi:10.1111/j.1365-2036.2005.02579.x PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.